Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00791
|
|||||
| Drug Name |
Sparfloxacin
|
|||||
| Synonyms |
(cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid; AT 4140; AT-4140; CP 103826; CP-103826; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; DRG-0143; Esparfloxacino; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD 131501; PD-131501; PD131501; RP-64206; Respipac (TN); SPFX; Spara; Sparfloxacin & RU 40555; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Sparfloxacin, cis-isomer; Sparfloxacine; Sparfloxacine [INN-French]; Sparfloxacinum; Sparfloxacinum [INN-Latin]; Zagam; Zagam (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H22F2N4O3
|
|||||
| Canonical SMILES |
CC1CN(CC(N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
|
|||||
| InChI |
InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
|
|||||
| InChIKey |
DZZWHBIBMUVIIW-DTORHVGOSA-N
|
|||||
| CAS Number |
CAS 110871-86-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 392.4 | Topological Polar Surface Area | 98.9 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
0.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:9212
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Sparfloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.